Authors: Rex, JH Walsh, TJ Nettleman, M Anaissie, EJ Bennett, JE Bow, EJ Carillo-Munoz, AJ Chavanet, P Cloud, GA Denning, DW de Pauw, BE Edwards, JE Hiemenz, JW Kauffman, CA Lopez-Berestein, G Martino, P Sobel, JD Stevens, DA Sylvester, R Tollemar, J Viscoli, C Viviani, MA Wu, T

Citation: Jh. Rex et al., Need for alternative trial designs and evaluation strategies for therapeutic studies of invasive mycoses, CLIN INF D, 33(1), 2001, pp. 95-106

Authors: Bow, EJ

Citation: Ej. Bow, Invasive aspergillosis in cancer patients, ONCOLOGY-NY, 15(8), 2001, pp. 1035-1039

Authors: Boogaerts, M Winston, DJ Bow, EJ Garber, G Reboli, AC Schwarer, AP Novitzky, N Boehme, A Chwetzoff, E De Beule, K

Citation: M. Boogaerts et al., Intravenous and oral itraconazole versus intravenous amphotericin B deoxycholate as empirical antifungal therapy for persistent fever in neutropenic patients with cancer who are receiving broad-spectrum antibacterial therapy- A randomized, controlled trial, ANN INT MED, 135(6), 2001, pp. 412-422

Authors: Laverdiere, M Rotstein, C Bow, EJ Roberts, RS Ioannou, S Carr, D Moghaddam, N

Citation: M. Laverdiere et al., Impact of fluconazole prophylaxis on fungal colonization and infection rates in neutropenic patients, J ANTIMICRO, 46(6), 2000, pp. 1001-1008

Authors: Rotstein, C Bow, EJ Laverdiere, M Ioannou, S Carr, D Moghaddam, N

Citation: C. Rotstein et al., Randomized placebo-controlled trial of fluconazole prophylaxis for neutropenic cancer patients: Benefit based on purpose and intensity of cytotoxic therapy, CLIN INF D, 28(2), 1999, pp. 331-340

Authors: Bow, EJ Kilpatrick, MG Clinch, JJ

Citation: Ej. Bow et al., Totally implantable venous access ports systems for patients receiving chemotherapy for solid tissue malignancies: A randomized controlled clinical trial examining the safety, efficacy, costs, and impact on quality of life, J CL ONCOL, 17(4), 1999, pp. 1267-1273